10-Q: Canopy Growth Narrows Losses, Boosts Cash Amid Debt Refinancing

Canopy Growth reported significantly reduced net losses and improved cash flow, driven by debt restructuring and new financing, despite ongoing gross margin pressures and a key U.S. investment default.

Summary

• Net loss from continuing operations significantly decreased to $62.6 million for the three months ended December 31, 2025, compared to $121.9 million in the prior year, and to $105.8 million for the nine months, down from $382.6 million.
• Adjusted EBITDA loss improved to $2.9 million for the quarter and $13.8 million for the nine months, compared to $3.5 million and $14.3 million respectively in the prior year periods.
• Cash and cash equivalents increased substantially to $371.3 million as of December 31, 2025, up from $113.8 million at March 31, 2025.
• Total debt outstanding decreased to $225.0 million as of December 31, 2025, from $304.1 million at March 31, 2025, with the Credit Facility fully repaid in January 2026 and Supreme Debentures settled.
• Net revenue remained relatively flat at $74.5 million for the quarter, but increased 5% to $213.4 million for the nine months, driven by Canadian cannabis growth.
• Gross margin percentage declined to 29% for both the three and nine months ended December 31, 2025, down from 32% and 34% respectively in the prior year periods.
• Canopy Growth entered into an agreement to acquire MTL Cannabis Corp. on December 14, 2025, for a mix of shares and cash, subject to various approvals.
• Acreage, a key U.S. cannabis investment held by Canopy USA, is currently in default under its Third ARCA debt agreement, posing a risk to Canopy Growth's investment.
• The company secured a new senior secured term loan of US$150 million cash (US$162.1 million principal) on January 8, 2026, and restructured a convertible debenture.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, primarily due to significant improvements in loss reduction, cash flow, and debt management. However, persistent gross margin pressure and the critical default of a key U.S. investment (Acreage) temper the overall sentiment, indicating ongoing operational challenges and strategic risks.

Positives

• Net loss from continuing operations decreased by 49% to $62.6 million for the three months ended December 31, 2025, and by 72% to $105.8 million for the nine months, indicating improved financial performance.
• Adjusted EBITDA loss narrowed to $2.9 million for the quarter and $13.8 million for the nine months, reflecting cost savings in selling, general, and administrative expenses.
• Cash and cash equivalents significantly increased to $371.3 million at December 31, 2025, from $113.8 million at March 31, 2025, bolstering liquidity.
• Net cash used in operating activities decreased substantially to $45.6 million for the nine months, down from $132.6 million in the prior year, demonstrating reduced cash burn.
• Total debt outstanding decreased to $225.0 million at December 31, 2025, from $304.1 million at March 31, 2025, with the Credit Facility fully repaid in January 2026 and Supreme Debentures fully settled.
• Canadian adult-use cannabis net revenue grew by 8% to $22.9 million for the quarter and 26% to $73.9 million for the nine months, driven by new product offerings.
• Canadian medical cannabis net revenue increased by 15% to $22.5 million for the quarter and $65.5 million for the nine months, due to more insured customers and larger order sizes.
• The proposed acquisition of MTL Cannabis Corp. is a strategic move to expand the Canadian cannabis portfolio.

Negatives

• Overall net revenue for the three months ended December 31, 2025, saw a slight decrease of 0.3% to $74.5 million.
• Gross margin percentage declined to 29% for both the three and nine months ended December 31, 2025, from 32% and 34% respectively, indicating pressure on profitability.
• International markets cannabis revenue decreased by 31% to $6.2 million for the quarter and 22% to $20.1 million for the nine months, primarily due to supply chain challenges in Europe.
• Storz & Bickel revenue decreased by 9% to $22.9 million for the quarter and 14% to $53.9 million for the nine months, attributed to strong prior-year sales and consumer economic uncertainty, along with increased tariffs on U.S. imports.
• Acquisition, divestiture, and other costs increased significantly to $10.8 million for the quarter, primarily due to legal costs related to the BioSteel restatement and MTL acquisition transaction costs.
• Fair value changes on Canopy USA related assets resulted in a $31.8 million expense for the quarter and $18.0 million for the nine months, reflecting decreases in investment value.

Risks

• The 2025 Budget in Canada proposes decreasing the reimbursement rate for medical cannabis for RCMP members and veterans from $8.50 per gram to $6.00 per gram, which could adversely affect profitability and medical cannabis revenues.
• There is no certainty that all conditions for the MTL Arrangement (acquisition of MTL Cannabis Corp.) will be satisfied or waived, including shareholder and regulatory approvals, which could lead to the acquisition not being completed and a potential decline in Canopy Shares.
• Acreage is currently in default under the Third ARCA, and the portion of Acreage and Wana Debt owing to the ARCA Lender ranks in priority to Canopy Growth's investment. This could result in Canopy Growth losing its entire investment in the Acreage and Wana Debt ($166.5 million / US$121.5 million) if the ARCA Lender enforces its security.
• If Acreage or Wana are unable to continue as a going concern, it would negatively impact Canopy USA's business, financial results, and operations, and adversely affect Canopy Growth's U.S. strategy and potentially its share price.
• The company is subject to an ongoing SEC investigation related to the BioSteel Review, and any remedial measures, sanctions, fines, or penalties could have a material adverse impact on the business.
• Ongoing putative class action lawsuits in Ontario and British Columbia allege misrepresentations in the company's disclosures, seeking unspecified damages.

Future Outlook

The company anticipates continued growth in Canadian adult-use and medical cannabis markets, driven by new product launches. It expects to complete the acquisition of MTL Cannabis Corp., which is subject to shareholder and regulatory approvals. The company will continue to pursue external financing sources, including equity and debt offerings, to ensure adequate financial resources. Management will perform its next annual goodwill impairment analysis on March 31, 2026. The potential impact of the proposed decrease in medical cannabis reimbursement rates in Canada is being evaluated.

Management Comments

• Management believes Adjusted EBITDA is a useful measure for investors because it provides meaningful and useful financial information, as this measure demonstrates the operating performance of business.
• Management considers assumptions regarding historical trends, current conditions, expected future developments, cash flow generation, economic conditions, production capabilities, consumer interest, competition, costs, government regulation, and timely receipt of regulatory authorizations to be reasonable based on information currently available.

Industry Context

StockSavvy.ai notes that Canopy Growth's performance reflects a broader trend in the Canadian cannabis market where established players are consolidating and focusing on profitability amidst intense competition. The growth in Canadian adult-use and medical cannabis, particularly with new product formats like infused PRJs and All-In-One vaporizers, aligns with evolving consumer preferences. However, the decline in international cannabis revenue due to supply chain issues highlights the fragility of global cannabis logistics and regulatory hurdles. The challenges faced by Storz & Bickel, including consumer economic uncertainty and tariffs, are indicative of broader discretionary spending pressures and trade complexities affecting consumer goods. The strategic focus on the U.S. market through Canopy USA, despite the current default of Acreage, underscores the industry's long-term view on U.S. federal legalization, which remains a significant catalyst.

Comparison to Industry Standards

• Canopy Growth's 29% gross margin percentage for the nine months ended December 31, 2025, is generally lower than some more established consumer packaged goods (CPG) companies, but within the range for a cannabis industry still facing significant regulatory and competitive pressures. For example, Tilray Brands (TLRY) has reported gross margins in the low to mid-20s, while some U.S. multi-state operators (MSOs) like Green Thumb Industries (GTII) or Curaleaf (CURA) often achieve higher gross margins (e.g., 40-50%) due to vertical integration and less excise tax burden in certain state markets.
• The significant reduction in net loss and Adjusted EBITDA loss, while positive, still indicates that the company is not yet consistently profitable. This contrasts with some U.S. MSOs that have achieved positive Adjusted EBITDA and, in some cases, net income, demonstrating more mature operational efficiency in their respective state markets.
• The increase in cash and cash equivalents to $371.3 million and the reduction in total debt reflect a strong focus on balance sheet health, which is a critical differentiator in the capital-intensive cannabis industry. This deleveraging and liquidity improvement position Canopy Growth more favorably compared to some peers that continue to struggle with high debt loads and limited access to capital.
• The default of Acreage under its debt agreement highlights the inherent risks and financial instability still present in the fragmented U.S. cannabis market, even for larger operators. This situation is a stark reminder of the challenges faced by companies operating in federally illegal markets, where traditional financing options are limited and M&A strategies carry elevated risks.

Management Changes

Corporate Governance

Legal Proceedings

• Dziedziejko v. Canopy Growth Corporation et al.: A putative class action in Ontario Superior Court of Justice alleging misrepresentations in disclosures between June 1, 2021, and June 22, 2023. The court granted leave to proceed and certified the action as a class proceeding on December 22, 2025.
• Asmaro v. Canopy Growth Corporation et al.: A putative class action in the Supreme Court of British Columbia alleging misrepresentations in disclosures between August 6, 2021, and May 10, 2023, seeking unspecified damages.
• SEC Investigation: The company is subject to an ongoing SEC investigation related to the BioSteel Review, which was voluntarily self-reported. The outcome and potential impact, including remedial measures, sanctions, fines, or penalties, cannot be predicted.
• Baron v. Canopy Growth Corporation et al.: A putative class action in the U.S. District Court for the Eastern District of New York alleging false/misleading statements regarding Claybourne pre-rolled joints and Storz & Bickel costs. This action was voluntarily dismissed without prejudice on January 22, 2026, and the case was terminated on January 23, 2026.

Related Party Transactions

• Canopy Growth holds non-voting and non-participating shares in Canopy USA and an interest in the Canopy USA LPs, which are classified as equity method investments and accounted for at fair value.
• The Elevate loan receivable, previously an intercompany loan, is now considered a related party loan upon deconsolidation of Canopy USA and is recognized at fair value.
• The Acreage and Wana Debt includes approximately $166.5 million (US$121.5 million) owing to a wholly-owned subsidiary of Canopy Growth (the Optionor), which is subordinate to debt owed to an arms-length third-party lender (ARCA Lender).

Stakeholder Impact

• Shareholders: Potential positive impact from reduced losses, improved cash flow, and debt reduction. However, dilution from ATM programs and warrant issuances, along with risks from Acreage's default and ongoing legal proceedings, could create volatility. The proposed MTL acquisition could offer growth opportunities.
• Employees: Continued reductions in headcount are noted, impacting employee morale and job security. Restructuring costs primarily related to employee restructuring.
• Customers (Canadian Adult-Use & Medical): Increased product assortment and new offerings in Canadian adult-use and medical cannabis markets. Medical cannabis customers (RCMP, VAC) may face higher out-of-pocket costs if the proposed reimbursement adjustment is implemented.
• Lenders/Creditors: The repayment of the Credit Facility and settlement of Supreme Debentures, along with securing a new senior secured term loan, demonstrates active debt management and access to capital. However, the default of Acreage's debt, where Canopy Growth is a subordinate lender, poses a risk to its investment.
• Suppliers: Supply chain challenges in Europe impacted international cannabis revenue, potentially affecting relationships with international suppliers.

Next Steps

• Complete the acquisition of MTL Cannabis Corp., subject to approval by the Supreme Court of British Columbia, Competition Act (Canada) approval, and MTL shareholder approval at a meeting scheduled for February 17, 2026.
• Perform the next annual goodwill impairment analysis on March 31, 2026.
• Continue to evaluate the impact of the proposed 2025 Budget's medical cannabis reimbursement adjustment on profitability and revenues.
• Monitor and address the default of Acreage under the Third ARCA and its potential impact on Canopy USA's business and the company's U.S. strategy.
• Utilize the remaining capacity of the August 2025 ATM Program (up to US$102.0 million) for further equity financings.
• Manage the new senior secured term loan and January 2026 Convertible Debentures, including interest payments and potential prepayments.

Key Dates

Recommendation

Canopy Growth's latest filing presents a mixed but generally improving financial picture, warranting a 'hold' recommendation. The significant reduction in net losses and Adjusted EBITDA losses, coupled with a substantial increase in cash and successful debt restructuring, demonstrates a stronger financial foundation and improved operational efficiency. The strategic acquisition of MTL Cannabis is a positive step for the Canadian market. However, persistent gross margin pressures, declining international and Storz & Bickel revenues, and the critical default of Acreage, a key U.S. investment, introduce considerable uncertainty and risk. The ongoing SEC investigation and class action lawsuits also remain overhangs. While the company has made strides in shoring up its balance sheet, the path to sustainable profitability and the resolution of U.S. market entry challenges are not yet clear enough to warrant a 'buy' recommendation. Investors should hold to observe the execution of the MTL integration, the resolution of the Acreage situation, and the company's ability to achieve consistent positive free cash flow and gross margin expansion.

Keywords

Cannabis, Marijuana, SEC Filing, 10-Q, Canopy Growth, CGC, Financial Results, Earnings, Debt Restructuring, Capital Raise, MTL Cannabis, Acquisition, Canopy USA, Acreage Holdings, Wana, Jetty, TerrAscend, Storz & Bickel, Medical Cannabis, Adult-Use Cannabis, Canada, United States, Germany, Australia, Vaporizers, Edibles, Legal Proceedings, Risk Factors, Liquidity, Adjusted EBITDA